Clinical Trials Browser

Phase 2 × Unknown × ofatumumab × Clear all

NCT03280160 2022-09-16

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Phase 2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell